Trial
NCT04867837
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Octapharma
Collaborators
—
Condition
Acute Major Bleeding
Intervention
Octaplex
Why stopped
Following Interim Analysis IDMEAC concluded:1-No safety concerns 2-Suspend enrolment: Futility based on treatment effect size at interim analysis. Enrollment was suspended on 22DEC25. Study was terminated FEB2026. Final analysis is planned in Q2 2026
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-25